Book a demo

Chemical intelligence powered by cypris.ai

MD bacitracin

(4R)-5-[[(2S,3S)-1-[[(2S)-6-amino-1-[[(2R)-5-amino-1-[[(2S,3S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[2-(1-amino-2-methylbutyl)-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid;(2-hydroxybenzoyl)oxymethyl 2-hydroxybenzoate · also: bacitracin MD, Bacitracin methylenedisalicylate, Bacitracin methylene disalicylate, Bacitracin methylenedisalicylic acid

FormulaC81H117N17O23S
Mol. weight1728.983
PubChem CID11980094
InChIKeyPOMORUSPLDFVEK-PHXAWWDYSA-N
SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C3CSC(=N3)C(C(C)CC)N.C1=CC=C(C(=C1)C(=O)OCOC(=O)C2=CC=CC=C2O)O
819Patents
46Research papers
113Patents - last 3 years
5Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Warsaw Orthopedic Inc75
2EIDP Inc22
3Massachusetts Institute of Technology22
4University of Nebraska System17
5The University of Texas System15
6Novus International Inc12
7Boston Children's Hospital11
8Alnylam Pharmaceuticals Inc9
9Pioneer Hi-Bred International Inc9
10Coley Pharmaceutical GmbH8

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations556
2A61PTherapeutic activity (drug indications)431
3A23KAnimal feeds189
4C12NMicroorganisms, enzymes177
5Y02AClimate change adaptation122
6C07KPeptides112
7A61B50
8C12R46
9A61F44
10A61LSterilising / disinfecting materials41

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
Bacitracin methylene disalicylate- and dinitolmide-containing soluble powder2015QINGDAO KDN PHARMACEUTICAL CO., LTD.3
Bacitracin methylene disalicylate- and ivermectin-containing soluble powder2015QINGDAO KDN PHARMACEUTICAL CO., LTD.1
Preparation method of bacitracin methylene disalicylate2024QILU PHARMACEUTICAL (INNER MONGOLIA) Co.,Ltd.0
Soluble powder containing bacitracin methylene disalicylate and clopidol2015QINGDAO KDN PHARMACEUTICAL CO., LTD.0
Bacitracin methylene disalicylate- and decoquinate-containing soluble powder2015QINGDAO KDN PHARMACEUTICAL CO., LTD.0

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1M.D. SimsGraf Research (United States)5
2P.W. WaldroupUniversity of Arkansas at Fayetteville4
3Greg F. MathisU.S. National Poultry Research Center3
4Hyun S. LillehojBeltsville Agricultural Research Center3
5RALPH V. FELL3
6B.L. DamronUniversity of Florida2
7Brett Lumpkins2
8H. HellwigUniversity of Arkansas at Fayetteville2
9J. R. HernándezAuburn University2
10J.I. VargasAuburn University2

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of MD bacitracin?

MD bacitracin has the molecular formula C81H117N17O23S and a molecular weight of 1728.983 g/mol.

Which assignee holds the most patents related to MD bacitracin?

Warsaw Orthopedic Inc holds the most patents with 75 patents related to MD bacitracin, followed by EIDP Inc and Massachusetts Institute of Technology, each with 22 patents.

What are the primary patent classifications for MD bacitracin technology?

The primary patent classifications are A61K (556 patents), A61P (431 patents), and A23K (189 patents), indicating applications in pharmaceuticals, medical treatments, and animal feed respectively.

Who are the most prolific authors publishing on MD bacitracin?

M.D. Sims from Graf Research is the most prolific author with 5 papers, followed by P.W. Waldroup from University of Arkansas at Fayetteville with 4 papers on MD bacitracin.

What is the research focus of the most-cited paper on MD bacitracin?

The most-cited paper, with 204 citations, is titled 'Effects of Dietary Mannan Oligosaccharide, Bacitracin Methylene Disalicylate, or Both on the Live Performance and Intestinal Microbiology of Turkeys' and focuses on Animal Nutrition and Physiology.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial